Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Cipla
Mallinckrodt
Citi
Medtronic
Colorcon
Dow
Deloitte
Merck

Generated: September 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,855,246

« Back to Dashboard

Title:Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
Inventor(s): Demopulos; Gregory A. (Mercer Island, WA), Shen; Hui-rong (Bothell, WA), Tedford; Clark E. (Poulsbo, WA)
Assignee: Omeros Corporation (Seattle, WA)
Filing Date:Sep 28, 2016
Application Number:15/278,514
Claims:1. A liquid intraocular ophthalmic pharmaceutical solution dosage form consisting essentially of phenylephrine, ketorolac, and a buffer system, in solution in a pH-adjusted aqueous carrier as a solvent, that is free of preservatives, antioxidants and solubilizing agents, and a nitrogen gas overlay in a single-use container, wherein the phenylephrine is included at a concentration of 45 mM to 76 mM and the ketorolac is included at a concentration of about 8.5 mM to 14 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

2. The dosage form of claim 1, wherein the dosage form is free of visible precipitation and crystallization.

3. The dosage form of claim 2, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least 24 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

4. The dosage form of claim 3, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

5. The dosage form of claim 1, wherein the buffer system comprises an about 20 mM sodium citrate buffer system.

6. The dosage form of claim 1, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM.

7. The dosage form of claim 1, wherein the solution has a pH of from 5.8 to 6.8.

8. The dosage form of claim 7, wherein the pH of the solution is adjusted by adding sodium hydroxide and/or hydrochloric acid as may be required.

9. The dosage form of claim 1, wherein: the dosage form is free of visible precipitation and crystallization; the buffer system comprises an about 20 mM sodium citrate buffer system; the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM; the solution has a pH of from 5.8 to 6.8 that has been adjusted with sodium hydroxide and/or hydrochloric acid as may be required.

10. A liquid intraocular ophthalmic pharmaceutical solution consisting essentially of phenylephrine, ketorolac, and a sodium citrate buffer system, in solution in an aqueous carrier as a solvent that is adjusted to a pH of from 5.8 to 6.8, that is free of preservatives, antioxidants and solubilizing agents, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

11. The solution of claim 10, wherein the solution is free of visible precipitation and crystallization.

12. The solution of claim 10, wherein the solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

13. A liquid intraocular ophthalmic pharmaceutical solution comprising phenylephrine, ketorolac, and a sodium citrate buffer system, in solution in an aqueous carrier as a solvent that is adjusted to a pH of from 5.8 to 6.8, that is free of preservatives, antioxidants and solubilizing agents, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

14. The solution of claim 13, wherein the solution is free of visible precipitation and crystallization.

15. The solution of claim 13, wherein the solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
Chinese Patent Office
Queensland Health
Healthtrust
Fuji
Julphar
Accenture
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.